Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
Empliciti (elotuzumab) is a humanized monoclonal antibody against human CS1, which induces antibody-dependent cellular cytotoxicity in CS1-positive cells (PMID: 26005365). Empliciti (elotuzumab) is approved in combination with Revlimid (lenalidomide) and dexamethasone for use in patients with multiple myeloma (FDA.gov).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Elotuzumab||Empliciti||BMS-901608||Empliciti (elotuzumab) is a humanized monoclonal antibody against human CS1, which induces antibody-dependent cellular cytotoxicity in CS1-positive cells (PMID: 26005365). Empliciti (elotuzumab) is approved in combination with Revlimid (lenalidomide) and dexamethasone for use in patients with multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04517851||Phase I||Elotuzumab||Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis||Recruiting||USA||0|
|NCT02726581||Phase III||Elotuzumab Nivolumab Dexamethasone + Pomalidomide||Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma||Completed||USA | ITA | ESP | DEU | CAN | AUT||9|
|NCT02654132||Phase II||Dexamethasone + Pomalidomide Elotuzumab||Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma||Completed||USA | ITA | FRA | ESP | DEU | CAN||5|
|NCT02375555||Phase II||Elotuzumab Bortezomib + Dexamethasone + Lenalidomide||Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM||Active, not recruiting||USA||0|
|NCT01729091||Phase Ib/II||Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide||Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma||Active, not recruiting||USA||0|
|NCT01668719||Phase Ib/II||Elotuzumab Bortezomib + Dexamethasone + Lenalidomide||S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma||Active, not recruiting||USA||0|
|NCT02252263||Phase I||Urelumab Lirilumab Elotuzumab||A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma||Completed||USA | ESP||0|